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t6w WClqZ pozostaje w obserwacji.
U 4 chorych w momencie wtqczenia
do terapii istniaty masywne przerzuty, czas
przezycia w tych przypadkach wynosit
3 lub 4 miesiqce. W grupie z wyci~tymi
makroskopowymi przerzutami sredni czas
przezycia wynosi 20 m-cy (od 8 do 50).
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Brain metastases are associated with
poor prognosis. Median survival of such
melanoma patients is 4 month. Standard
treatment comprises palliative radiation
therapy or palliative excision of solitary
metastases in selected patients. Only
patients with resected solitary metastases
live a few months longer. The aim of this
study was to asses results and toxicity of
combined treatment with GMTV and
irradiation in melanoma patients, who
developed brain metastases. Since 1996
in Department of Cancer Immunology
Great Poland Cancer Centre a group of
250 melanoma patients was treated with
GMTV consisted of allogenic melanoma
cell lines Mich1 and Mich2 modified with
IL-6 and .sll-6.R genes or fu.s.iongene lL-
6/sIL-6R. All patients were stage III and IV
(AJCC). Before or during the immunization
22 patients presented symptoms of brain
metastases. All patients were irradiated
with the doses 30-39 Gy, using 3
Gy/fraction, 5 fractions/week. Toxicity and
clinical results (CT, OS) were evaluated. In
part of patients CTL and NK cytotoxicity
and Th1 vs. Th2 profiles were evaluated in
vitro. Side effects of irradiation were
tolerable, 0-2 degree according to WHO
criteria (standard dexamethasone treat-
ment in all patients). There were no radia-
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tion encephalopathy or radiation necrosis.
In 12/22 patients stabilization or partial
remission were observed. Overall survival
measured from brain metastases diagno-
sis ranged from 2 to 20 months. Median
survival was 9 months. In 12 responder
patients median survival was 13 months,
ranged from 7 to 20 months. In 10
remaining patients median survival was 4
months. There were no differences in CTL
activity but we noticed changes in NK
activity and Th1/Th2 ratio (pooled in Th1
direction) after irradiation. Radiotherapy
combined with GMTV compared with
radiotherapy alone prolongs survival in
melanoma patients, who developed brain
metastases.
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Sarcomas and solid tumors account
about 30% of children malignancies.
Among soft tissue tumors Rhabdomyosar-
coma (RMS) is most frequent neoplasm.
Some sarcomas and solid tumors of
childhood belong to the very diagnostically
difficult group called "small round cell
tumors". MyoD1 and Myf-3 genes products
are very promising markers of tumor
myoQjIDic di.fferentiation. 65 formalin-fixed
and paraffin-embedded tissue sections
from cases diagnosed in the Laboratory of
Pathology Institute of Pediatry, Medical
University of Lodz were selected for our
study. There were 30 cases of RMSs
(4 botryoid, 16 embryonal, 8 alveolar,
2 solid), 10 cases of neuroblastomas,
5 cases of pPNETs and 5 cases of
synovial-tenosynovial sarcomas, as well
as 5 cases of Wilms tumors. For immu-
nohistochemistry we applied antibodies
against MyoD1 and Myf-3 gene products,
against sarcomeric actin, desmin, myo-
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